サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1427919

ネオアンチゲン標的療法の世界市場レポート 2024

Neoantigen Targeted Therapies Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 175 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
ネオアンチゲン標的療法の世界市場レポート 2024
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

ネオアンチゲン標的療法の市場規模は、今後数年間で急激に成長すると予想されています。 2028年には36.3%の年間複合成長率（CAGR）で116億9,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、バイオインフォマティクスの進歩、精密医療の拡大、ネオアンチゲンワクチンの開発、治療併用戦略の採用、バイオマーカーの検証によってもたらされると予想されます。予測期間における注目すべき動向には、ネオアンチゲン耐性の管理、ネオアンチゲン初回刺激養子細胞療法の利用、ネオアンチゲンに基づく併用療法の探索、実世界データの統合、予測モデルの強化が含まれます。

ネオアンチゲン標的療法市場で予想される成長は、主にがんの発生率の増加によるものです。これは、特定の期間における特定の集団内での新たながん症例の増加を指します。 ネオアンチゲン標的療法は、多くの場合、組み合わせて投与され、さまざまな種類のがんの治療に役立ちます。米国がん協会は、2022年に米国の新規がん症例数が大幅に増加し、190万人に達したと報告しました。さらに、同年には60万9,360人ががんで死亡しており、がんの深刻な影響が浮き彫りとなった。したがって、がん罹患率の急増は、ネオアンチゲン標的療法市場の成長を推進する重要な原動力となっています。

市場の成長は、精密腫瘍学のますます顕著になることによって促進されると予想されます。高精度腫瘍学には、患者の腫瘍に関する詳細な遺伝情報および分子情報に基づいて、がん治療を調整することが含まれます。ネオアンチゲン標的療法は、高度なゲノム解析を利用して個人のがん細胞によって発現される固有のネオアンチゲンを特定することにより、精密腫瘍学において極めて重要な役割を果たします。このアプローチにより、各患者の腫瘍の特定の遺伝子構造に対処し、より個別化された効果的な治療オプションが可能になります。ノバルティス AGが2021年のプレシジョンオンコロジー年次トレンドレポートで報告したように、プレシジョンオンコロジーの普及は、次世代シーケンス（NGS）の採用の増加で明らかであり、腫瘍専門医の60%が症例の75%以上でNGSを頻繁に使用しています。これは、精密腫瘍学のアプローチから恩恵を受けるがん患者の割合が増加していることを意味します。したがって、精密腫瘍学の台頭は、ネオアンチゲン標的療法市場の成長を促進する重要な要因です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年～2023年
  • 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

  • 世界のネオアンチゲン標的療法市場、タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 単独療法
  • 併用療法
  • 世界のネオアンチゲン標的療法市場、免疫療法タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • DNAまたはRNAベースのワクチン
  • タンパク質ベースのワクチン
  • 樹状細胞ワクチン
  • TILベースの治療法
  • 世界のネオアンチゲン標的療法市場、標的疾患適応別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 結腸直腸がん
  • 腎細胞がん
  • 非小細胞肺がん
  • 骨がん
  • 婦人科がん
  • 世界のネオアンチゲン標的療法市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 皮内
  • 静脈内
  • 皮下
  • 世界のネオアンチゲン標的療法市場、用途別のセグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 医療研究機関
  • 病院とクリニック
  • その他の用途

第7章 地域および国の分析

  • 世界のネオアンチゲン標的療法市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界のネオアンチゲン標的療法市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ネオアンチゲン標的療法市場の競合情勢
  • ネオアンチゲン標的療法市場の企業プロファイル
    • F. Hoffmann-La Roche AG
    • Merck and Co. Inc.
    • Bristol Myers Squibb Company
    • GlaxoSmithKline plc
    • Eli Lilly and Company

第31章 その他の大手および革新的な企業

  • Kite Pharma Inc.
  • Gilead Sciences Inc.
  • Amgen Inc.
  • Moderna Inc.
  • BioNTech SE
  • Bavarian Nordic Inc.
  • Advaxis Inc.
  • Immatics NV
  • Precision Biologics Inc.
  • Iovance Biotherapeutics Inc.
  • Agenus Inc.
  • Achilles Therapeutics Plc
  • Medigene AG
  • Gritstone Bio Inc.
  • SQZ Biotechnologies Company

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

目次
Product Code: r13763

Neoantigen-targeted therapies represent a precision medicine approach focused on leveraging neoantigens within cancer cells. Neoantigens, distinct antigens arising from genetic abnormalities in cancer cells, become the target for harnessing the body's immune system to specifically identify and combat cancer.

These therapies fall into two main categories, monotherapy and combination therapy. Monotherapy involves utilizing a single medicine or therapeutic approach to address the disease. Immunotherapy options encompass DNA or RNA-based vaccines, protein-based vaccines, dendritic cell vaccines, and TIL-based therapies, with applications spanning colorectal cancer, renal cell carcinoma, non-small cell lung cancer, bone cancer, and gynecological cancer. Administration routes include intradermal, intravenous, and subcutaneous, while applications extend to medical research institutions, hospitals, clinics, and other healthcare settings.

The neoantigen targeted therapies market research report is one of a series of new reports from The Business Research Company that provides neoantigen targeted therapies market statistics, including the neoantigen targeted therapies industry global market size, regional shares, competitors with a neoantigen targeted therapies market share, detailed neoantigen targeted therapies market segments, market trends, and opportunities, and any further data you may need to thrive in the neoantigen targeted therapies industry. This neoantigen targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The neoantigen targeted therapies market size has grown exponentially in recent years. It will grow from $2.43 billion in 2023 to $3.39 billion in 2024 at a compound annual growth rate (CAGR) of 39.3%. The growth observed during the historical period can be attributed to several factors, including advancements in genomic sequencing, the evolution of immunotherapy, increased understanding of tumor immunology, the successful implementation of checkpoint inhibitors in clinical settings, and progress in molecular profiling technologies.

The neoantigen targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $11.69 billion in 2028 at a compound annual growth rate (CAGR) of 36.3%. The anticipated growth in the forecast period is expected to result from advancements in bioinformatics, the expansion of precision medicine, the development of neoantigen vaccines, the adoption of therapeutic combination strategies, and the validation of biomarkers. Noteworthy trends in the forecast period encompass the management of neoantigen resistance, the utilization of neoantigen-primed adoptive cell therapies, the exploration of neoantigen-based combinatorial therapies, the integration of real-world data, and the enhancement of predictive models.

The anticipated growth in the neoantigen targeted therapies market is primarily attributed to the increasing incidence of cancer cases. This refers to the rise in new cancer cases within a specific population during a given period. Neoantigen targeted therapies, often administered in combination, are instrumental in treating various types of cancer. In 2022, the American Cancer Society reported a substantial increase in new cancer cases in the United States, reaching 1.9 million. Additionally, 609,360 deaths were attributed to cancer in the same year, underscoring the profound impact of the disease. Consequently, the surge in cancer incidence is a key driver propelling the growth of the neoantigen targeted therapies market.

The growth of the market is expected to be fueled by the increasing prominence of precision oncology. Precision oncology involves tailoring cancer treatment based on detailed genetic and molecular information about a patient's tumor. Neoantigen-targeted therapies play a pivotal role in precision oncology by utilizing advanced genomic analysis to identify unique neoantigens expressed by an individual's cancer cells. This approach allows for a more personalized and effective treatment option, addressing the specific genetic makeup of each patient's tumor. The prevalence of precision oncology is evident in the increasing adoption of next-generation sequencing (NGS), with 60% of oncologists frequently using NGS in over 75% of cases, as reported by Novartis AG in its 2021 precision oncology annual trend report. This signifies a growing percentage of cancer patients benefiting from the precision oncology approach. Consequently, the rise of precision oncology is a key factor driving the growth of the neoantigen targeted therapies market.

Product innovation has become a prominent trend within the neoantigen targeted therapies market, with major players prioritizing the development of inventive products to establish leadership. A notable example is BioNTech, a Germany-based biotechnology company, which, in October 2021, expanded its clinical oncology portfolio by initiating a Phase 2 clinical trial for 'BNT122,' an mRNA-based individualized immunotherapy. This trial, focusing on colorectal cancer patients, represents a significant milestone, with the first patient dosed with BNT122. The innovative approach of stimulating a targeted T-cell response against neoantigens in each patient's tumor showcases BioNTech's commitment to advancing cutting-edge immunotherapies and broadening treatment options for cancer patients.

Key players in the neoantigen targeted therapies market are adopting a strategic partnership approach to personalize neoantigen vaccines and monoclonal antibody drugs, addressing challenges in existing immunotherapy for solid tumors. Strategic partnerships involve leveraging complementary strengths and resources for mutual benefits. An example is the partnership between Innovent Biologics, a China-based biopharmaceutical company, and NeoCura Bio-Medical Technology Co. Ltd., a China-based precision healthcare and medical technology company. Their collaboration, initiated in October 2021, aims to evaluate the combination therapy of sintilimab and the neoantigen vaccine NEO_PLIN2101 for cancer treatment in China, assessing safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in cancer patients.

In August 2021, BioNTech SE, another Germany-based biotechnology company, acquired Kite Pharma's Neoantigen TCR cell therapy platform, further exemplifying the commitment to leveraging the immune system to combat cancer. This strategic move not only strengthens BioNTech's position in the innovative cell-based therapies field but also aligns with the company's broader goals in advancing cancer treatment. Kite Pharma, a US-based company specializing in cell therapy and immunotherapy, operates within the neoantigen targeted therapies market.

Major companies operating in the neoantigen targeted therapies market report are F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline PLC, Eli Lilly and Company, Kite Pharma Inc., Gilead Sciences Inc., Amgen Inc., Moderna Inc., BioNTech SE, Bavarian Nordic Inc., Advaxis Inc., Immatics NV, Precision Biologics Inc., Iovance Biotherapeutics Inc., Agenus Inc., Achilles Therapeutics PLC, Medigene AG, Gritstone Bio Inc., SQZ Biotechnologies Company, Aduro BioTech Inc., Inovio Pharmaceuticals Inc., Gradalis Inc., EpiVax Inc., ISA Pharmaceuticals BV, Vaxon Biotech SA, Ziopharm Oncology, Genocea Biosciences Inc., Cellular Biomedicine Group Inc., Immunovaccine Inc.

North America was the largest region in the neoantigen targeted therapies market in 2023. The regions covered in the neoantigen targeted therapies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the neoantigen targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neoantigen targeted therapies market consists of revenues earned by entities by providing services such as the identification and characterization of neoantigens in individual patients, the selection and administration of the appropriate therapy, and the monitoring of patients' responses. The market value includes the value of related goods sold by the service provider or included within the service offering. Neoantigen targeted therapies also include the sale of neoantigen-based cancer vaccines and genetically modified T cells. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neoantigen Targeted Therapies Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neoantigen targeted therapies market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neoantigen targeted therapies ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neoantigen targeted therapies market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

  • 1) By Type: Monotherapy; Combination Therapy
  • 2) By Immunotherapy Type: DNA Or RNA-Based Vaccines; Protein-Based Vaccines; Dendritic Cell Vaccines; TIL-Based Therapies
  • 3) By Target Disease Indication: Colorectal Cancer; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Bone Cancer; Gynecological Cancer
  • 4) By Route of Administration: Intradermal; Intravenous; Subcutaneous
  • 5) By Application: Medical Research Institution; Hospital; and Clinic; Other Applications
  • Companies Mentioned: F. Hoffmann-La Roche AG; Merck and Co. Inc.; Bristol Myers Squibb Company; GlaxoSmithKline plc; Eli Lilly and Company
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neoantigen Targeted Therapies Market Characteristics

3. Neoantigen Targeted Therapies Market Trends And Strategies

4. Neoantigen Targeted Therapies Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Neoantigen Targeted Therapies Market Size and Growth

  • 5.1. Global Neoantigen Targeted Therapies Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Neoantigen Targeted Therapies Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Neoantigen Targeted Therapies Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Neoantigen Targeted Therapies Market Segmentation

  • 6.1. Global Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monotherapy
  • Combination Therapy
  • 6.2. Global Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • DNA Or RNA-Based Vaccines
  • Protein-Based Vaccines
  • Dendritic Cell Vaccines
  • TIL-Based Therapies
  • 6.3. Global Neoantigen Targeted Therapies Market, Segmentation By Target Disease Indication, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Colorectal Cancer
  • Renal Cell Carcinoma
  • Non-Small Cell Lung Cancer
  • Bone Cancer
  • Gynecological Cancer
  • 6.4. Global Neoantigen Targeted Therapies Market, Segmentation By Route of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Intradermal
  • Intravenous
  • Subcutaneous
  • 6.5. Global Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medical Research Institution
  • Hospital And Clinic
  • Other Applications

7. Neoantigen Targeted Therapies Market Regional And Country Analysis

  • 7.1. Global Neoantigen Targeted Therapies Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Neoantigen Targeted Therapies Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Neoantigen Targeted Therapies Market

  • 8.1. Asia-Pacific Neoantigen Targeted Therapies Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Neoantigen Targeted Therapies Market

  • 9.1. China Neoantigen Targeted Therapies Market Overview
  • 9.2. China Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Neoantigen Targeted Therapies Market

  • 10.1. India Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Neoantigen Targeted Therapies Market

  • 11.1. Japan Neoantigen Targeted Therapies Market Overview
  • 11.2. Japan Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Neoantigen Targeted Therapies Market

  • 12.1. Australia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Neoantigen Targeted Therapies Market

  • 13.1. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Neoantigen Targeted Therapies Market

  • 14.1. South Korea Neoantigen Targeted Therapies Market Overview
  • 14.2. South Korea Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Neoantigen Targeted Therapies Market

  • 15.1. Western Europe Neoantigen Targeted Therapies Market Overview
  • 15.2. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Neoantigen Targeted Therapies Market

  • 16.1. UK Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Neoantigen Targeted Therapies Market

  • 17.1. Germany Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Neoantigen Targeted Therapies Market

  • 18.1. France Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Neoantigen Targeted Therapies Market

  • 19.1. Italy Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Neoantigen Targeted Therapies Market

  • 20.1. Spain Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Neoantigen Targeted Therapies Market

  • 21.1. Eastern Europe Neoantigen Targeted Therapies Market Overview
  • 21.2. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Neoantigen Targeted Therapies Market

  • 22.1. Russia Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Neoantigen Targeted Therapies Market

  • 23.1. North America Neoantigen Targeted Therapies Market Overview
  • 23.2. North America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Neoantigen Targeted Therapies Market

  • 24.1. USA Neoantigen Targeted Therapies Market Overview
  • 24.2. USA Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Neoantigen Targeted Therapies Market

  • 25.1. Canada Neoantigen Targeted Therapies Market Overview
  • 25.2. Canada Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Neoantigen Targeted Therapies Market

  • 26.1. South America Neoantigen Targeted Therapies Market Overview
  • 26.2. South America Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Neoantigen Targeted Therapies Market

  • 27.1. Brazil Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Neoantigen Targeted Therapies Market

  • 28.1. Middle East Neoantigen Targeted Therapies Market Overview
  • 28.2. Middle East Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Neoantigen Targeted Therapies Market

  • 29.1. Africa Neoantigen Targeted Therapies Market Overview
  • 29.2. Africa Neoantigen Targeted Therapies Market, Segmentation By Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Neoantigen Targeted Therapies Market, Segmentation By Immunotherapy Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Neoantigen Targeted Therapies Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Neoantigen Targeted Therapies Market Competitive Landscape And Company Profiles

  • 30.1. Neoantigen Targeted Therapies Market Competitive Landscape
  • 30.2. Neoantigen Targeted Therapies Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Merck and Co. Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Bristol Myers Squibb Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. GlaxoSmithKline plc
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Eli Lilly and Company
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Neoantigen Targeted Therapies Market Other Major And Innovative Companies

  • 31.1. Kite Pharma Inc.
  • 31.2. Gilead Sciences Inc.
  • 31.3. Amgen Inc.
  • 31.4. Moderna Inc.
  • 31.5. BioNTech SE
  • 31.6. Bavarian Nordic Inc.
  • 31.7. Advaxis Inc.
  • 31.8. Immatics NV
  • 31.9. Precision Biologics Inc.
  • 31.10. Iovance Biotherapeutics Inc.
  • 31.11. Agenus Inc.
  • 31.12. Achilles Therapeutics Plc
  • 31.13. Medigene AG
  • 31.14. Gritstone Bio Inc.
  • 31.15. SQZ Biotechnologies Company

32. Global Neoantigen Targeted Therapies Market Competitive Benchmarking

33. Global Neoantigen Targeted Therapies Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Neoantigen Targeted Therapies Market

35. Neoantigen Targeted Therapies Market Future Outlook and Potential Analysis

  • 35.1 Neoantigen Targeted Therapies Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Neoantigen Targeted Therapies Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Neoantigen Targeted Therapies Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer